A Randomized Phase II Study of Nivolumab versus Nivolumab and BMS-986016 (Relatimab) as Maintenance Treatment after First-line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus- Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)

Sponsor:

NRG

Sponsor Study ID:

NRG-HN011

CTO #:

104051

NCT Number:

NCT06029270

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Lip, Oral Cavity and Pharynx

Study Objectives:

To determine if adding BMS-986016 to nivolumab maintenance therapy shows a signal of improved progression free survival according to RECIST 1.1 in patients who do not progress following treatment with platinum gemcitabine nivolumab combination in the first line treatment of recurrent and/ or metastatic nasopharyngeal carcinoma.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)